The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice. 2014

Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou 510150, China. lijj6116@163.com.

The goal of this study was to investigate the possible protective effects of sitagliptin against dyslipidemia-related kidney injury in apolipoprotein E knockout (apoE-/-) mice. Eight-week-old male apoE-/- mice were randomized to receive either a high fat diet (HFD, apoE-/- group) or HFD mixed with sitagliptin (sita + apoE-/- group) for 16 weeks. A control group of age- and gender-matched C57BL/6J mice were fed a HFD. The apoE-/- group exhibited increases in body weight and serum lipid levels in addition to high-density lipoprotein, and increases in 24-h urinary 8-hydroxy-2-deoxyguanosine and albuminuria excretion. Decreased insulin sensitivity was also observed in the apoE-/- group. These mice additionally contained enlargements of the glomerular mesangial matrix area, lipid deposition area, and renal interstitium collagen area. The apoE-/- group also demonstrated down-regulation of phosphorylated AMP-activated protein kinase (AMPK), increases in renal mRNA expression of transforming growth factor-beta 1 (TGF-β1) and fibronectin (FN), and increased protein expression of Akt, TGF-β1, FN and p38/ERK mitogen-activated protein kinase (MAPK). Sitagliptin treatment successfully ameliorated all the deleterious effects of dyslipidemia tested. To our knowledge, this is the first time that sitagliptin has been shown to reverse the renal dysfunction and structural damage induced by dyslipidemia in apoE-/- mice. Our results suggest that the renoprotective mechanism of sitagliptin may be due to a reduction in Akt levels, a restoration of AMPK activity, and inhibition of TGF-β1, FN, and p38/ERK MAPK signaling pathways.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D005353 Fibronectins Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins. Cold-Insoluble Globulins,LETS Proteins,Fibronectin,Opsonic Glycoprotein,Opsonic alpha(2)SB Glycoprotein,alpha 2-Surface Binding Glycoprotein,Cold Insoluble Globulins,Globulins, Cold-Insoluble,Glycoprotein, Opsonic,Proteins, LETS,alpha 2 Surface Binding Glycoprotein
D000068900 Sitagliptin Phosphate A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES. 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine,Januvia,MK 0431,MK-0431,MK0431,Sitagliptin,Sitagliptin Monophosphate Monohydrate,Sitagliptin Phosphate Anhydrous,Sitagliptin Phosphate Monohydrate,0431, MK,Anhydrous, Sitagliptin Phosphate,Monohydrate, Sitagliptin Monophosphate,Monohydrate, Sitagliptin Phosphate,Monophosphate Monohydrate, Sitagliptin,Phosphate Anhydrous, Sitagliptin,Phosphate Monohydrate, Sitagliptin,Phosphate, Sitagliptin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D048051 p38 Mitogen-Activated Protein Kinases A mitogen-activated protein kinase subfamily that regulates a variety of cellular processes including CELL GROWTH PROCESSES; CELL DIFFERENTIATION; APOPTOSIS; and cellular responses to INFLAMMATION. The P38 MAP kinases are regulated by CYTOKINE RECEPTORS and can be activated in response to bacterial pathogens. Mitogen-Activated Protein Kinase p38,p38 Mitogen-Activated Protein Kinase,p38 MAP Kinase,p38 MAPK,p38 Protein Kinase,p38 SAPK,MAP Kinase, p38,MAPK, p38,Mitogen Activated Protein Kinase p38,Protein Kinase, p38,p38 Mitogen Activated Protein Kinase,p38 Mitogen Activated Protein Kinases

Related Publications

Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
January 2012, Journal of the American College of Cardiology,
Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
October 2021, Vascular pharmacology,
Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
January 2017, Biomedicine hub,
Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
January 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
April 2016, Vascular pharmacology,
Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
February 2016, Oncology reports,
Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
November 2020, Scientific reports,
Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
January 2024, Current pharmaceutical biotechnology,
Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
April 2007, Drug metabolism and disposition: the biological fate of chemicals,
Jingjing Li, and Meiping Guan, and Chenzhong Li, and Fuping Lyv, and Yanmei Zeng, and Zongji Zheng, and Chengzhi Wang, and Yaoming Xue
September 1999, Journal of lipid research,
Copied contents to your clipboard!